Find Clinical Trial

Home » Find Clinical Trials » An Open-Label, Dose-escalation, Phase I/IIa Study to Determine the Maximum Tolerated Dose, Recommended Dose, Efficacy, Pharmacokinetics and Pharmacodynamics of the dual VEGFR-FGFR Tyrosine Kinase Inhibitor, E-3810, Given Orally as Single Agent to Patients With Advanced Solid Tumours.

An Open-Label, Dose-escalation, Phase I/IIa Study to Determine the Maximum Tolerated Dose, Recommended Dose, Efficacy, Pharmacokinetics and Pharmacodynamics of the dual VEGFR-FGFR Tyrosine Kinase Inhibitor, E-3810, Given Orally as Single Agent to Patients With Advanced Solid Tumours.

← Back

Study Phase	Phase 1-2

Therapeutic Area	Cancers

Indication	Solid tumors

Sponsor	Institut de Recherches Internationales Servier (I.R.I.S)

Active substance/ Medical device	LUCITANIB, S080881

Active Substance Code	S080881

Protocol Code	CL1-80881-007

EudraCT Code	2010-019121-37

NCT Code	NCT01283945

Documents and links

Results summary	READ MORE

Scientific publication	READ MORE

Servier Glossary of Terms

To ease the reading, we are developing a glossary of terms. In this glossary, we provide the lay terms used in our lay summaries and the corresponding medical terms. You will find the Servier Glossary of Terms on this link.